or Try an Advanced Search...

    Technical Analysis for ALVR - AlloVir, Inc.

    Grade Last Price % Change Price Change
    F 0.57 1.93% 0.01
    ALVR closed up 1.93 percent on Wednesday, November 20, 2024, on 1.96 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ALVR trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Doji - Bullish? Reversal 1.93%
    New 52 Week Low Weakness 1.93%
    Wide Bands Range Expansion 1.93%
    Oversold Stochastic Weakness 1.93%
    Wide Bands Range Expansion -1.54%
    Oversold Stochastic Weakness -1.54%
    Calm After Storm Range Contraction 0.19%
    Wide Bands Range Expansion 0.19%
    Older End-of-Day Signals for ALVR ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 21 hours ago
    1.5x Volume Pace about 21 hours ago
    Up 5% about 21 hours ago
    Up 3% about 21 hours ago
    Up 2% about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ALVR Chart by TradingView
    Basic chart:

    Profile

    AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Immune System Stem Cell Cell Therapy Gene Therapy Cell Biology Manufacturing Process Viruses Virus Viral Disease Immunity Covid 19 Zoonoses

    Is ALVR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 11 AlloVir and Kalaris enter merger to advance retinal disease therapies
    Nov 8 Kalaris to go public via reverse merger with AlloVir
    Nov 8 AlloVir falls after all-stock merger deal with Kalaris
    Nov 8 AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
    Oct 30 Discovering Opportunities: AlloVir And 2 Other US Penny Stocks
    Jul 31 Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
    See more ALVR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.485
    52 Week Low 0.5153
    Average Volume 329,819
    200-Day Moving Average 0.76
    50-Day Moving Average 0.78
    20-Day Moving Average 0.76
    10-Day Moving Average 0.63
    Average True Range 0.09
    RSI (14) 37.89
    ADX 29.64
    +DI 20.74
    -DI 25.18
    Chandelier Exit (Long, 3 ATRs) 0.77
    Chandelier Exit (Short, 3 ATRs) 0.80
    Upper Bollinger Bands 1.11
    Lower Bollinger Band 0.42
    Percent B (%b) 0.22
    BandWidth 89.76
    MACD Line -0.07
    MACD Signal Line -0.04
    MACD Histogram -0.0308
    Fundamentals Value
    Market Cap 65.03 Million
    Num Shares 114 Million
    EPS -1.67
    Price-to-Earnings (P/E) Ratio -0.34
    Price-to-Sales 0.00
    Price-to-Book 0.42
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.68
    Resistance 3 (R3) 0.69 0.66 0.67
    Resistance 2 (R2) 0.66 0.64 0.66 0.66
    Resistance 1 (R1) 0.62 0.62 0.64 0.61 0.65
    Pivot Point 0.59 0.59 0.60 0.58 0.59
    Support 1 (S1) 0.54 0.56 0.57 0.53 0.49
    Support 2 (S2) 0.51 0.54 0.51 0.48
    Support 3 (S3) 0.47 0.51 0.48
    Support 4 (S4) 0.46